Leveragen Partners with Cell Signaling Technology to Advance Reagent Antibody Innovation with Proprietary Nanobody Technology
Leveragen Inc., a Boston-based biotechnology company specializing in next-generation genetic models for antibody discovery, ...
PharmiWeb8d
AstraZeneca to acquire EsoBiotec to advance cell therapy ambition
AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...
AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition
EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca ( NASDAQ: AZN) for up to $1 billion, on a ...
EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapyMONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a ...
Fierce Biotech8d
AstraZeneca goes in vivo, penning $1B deal for Belgian off-the-shelf cell therapy biotech
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...
AstraZeneca to acquire biotech firm at cost of up to $1B
AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.
AstraZeneca to buy EsoBiotec for up to $1 billion
AstraZeneca is set to acquire biotechnology firm EsoBiotec for up to $1 billion, including a $425 million upfront payment and ...
AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details
AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion ...
PharmExec8d
AstraZeneca Acquires EsoBiotec; Strikes Deal with Alteogen to Develop Oncology Therapies
The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...